Abstract
From the prospective of a major oncology center in the United States, somatostatin analog radiopeptides currently have limited diagnostic and therapeutic utility. Diagnostic modalities utilitizing Somatostatin Receptor Imaging are now commercially available and the role of this type of method is currently being evaluated. Unlike the unique properties of thyroid tissue facilitating I-131 uptake, targeting of other tissues has required a carrier for the nuclide. Somastostatin peptide analogs have proved attractive based on the ubiquity of distribution and up-regulation in diseased tissue but prospective data is currently scarce. Interest in therapeutic applications of somatostatin analogs as carriers of yttrium, indium and more recently rhenium have resulted in trials with these agents both for endocrine and non-endocrine tumors. At this time, insufficient data exists to justify the indication of “first-line” therapy. The principles of Somatostatin Receptor Imaging and radiotherapy are discussed in this article along with the current status of these modalities in clinical practice as viewed by the author.
Keywords: therapeutic applications, somatostatin receptor, first-line therapy, neoplastic tissues, peptide receptor imaging and therapy
Current Pharmaceutical Design
Title: Diagnostic and Therapeutic Applications of Radiolabeled Somatostatin Analogs: Current Status in an Oncology Center
Volume: 8 Issue: 20
Author(s): Donald A. Podoloff
Affiliation:
Keywords: therapeutic applications, somatostatin receptor, first-line therapy, neoplastic tissues, peptide receptor imaging and therapy
Abstract: From the prospective of a major oncology center in the United States, somatostatin analog radiopeptides currently have limited diagnostic and therapeutic utility. Diagnostic modalities utilitizing Somatostatin Receptor Imaging are now commercially available and the role of this type of method is currently being evaluated. Unlike the unique properties of thyroid tissue facilitating I-131 uptake, targeting of other tissues has required a carrier for the nuclide. Somastostatin peptide analogs have proved attractive based on the ubiquity of distribution and up-regulation in diseased tissue but prospective data is currently scarce. Interest in therapeutic applications of somatostatin analogs as carriers of yttrium, indium and more recently rhenium have resulted in trials with these agents both for endocrine and non-endocrine tumors. At this time, insufficient data exists to justify the indication of “first-line” therapy. The principles of Somatostatin Receptor Imaging and radiotherapy are discussed in this article along with the current status of these modalities in clinical practice as viewed by the author.
Export Options
About this article
Cite this article as:
Podoloff A. Donald, Diagnostic and Therapeutic Applications of Radiolabeled Somatostatin Analogs: Current Status in an Oncology Center, Current Pharmaceutical Design 2002; 8 (20) . https://dx.doi.org/10.2174/1381612023393882
DOI https://dx.doi.org/10.2174/1381612023393882 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prostaglandin E<sub>2</sub> Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases
Current Chemical Biology Environmental Risk Assessment of Replication Competent Viral Vectors Applied in Clinical Trials: Potential Effects of Inserted Sequences
Current Gene Therapy 5-Benzylidene-3,4-dihalo-furan-2-one derivatives inhibit human leukemia cancer cells through suppression of NF-κB and GSK-3β
Anti-Cancer Agents in Medicinal Chemistry Role of Metabolic Enzymes P450 (CYP) on Activating Procarcinogen and their Polymorphisms on the Risk of Cancers
Current Drug Metabolism Intersection of MicroRNA and Gene Regulatory Networks and their Implication in Cancer
Current Pharmaceutical Biotechnology An Insight into Purine, Tyrosine and Tryptophan Derived Marine Antineoplastic Alkaloids
Anti-Cancer Agents in Medicinal Chemistry Combinatorial Application of Nucleic Acid-Based Agents Targeting Protein Kinases for Cancer Treatment
Current Pharmaceutical Design Fluorescent Molecular Imaging: Technical Progress and Current Preclinical and Clinical Applications in Urogynecologic Diseases
Current Molecular Medicine Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines
Protein & Peptide Letters Magnetic Resonance Nano-Theranostics for Glioblastoma Multiforme
Current Pharmaceutical Design Observations on the Use of the Avian Chorioallantoic Membrane (CAM) Model in Investigations into Angiogenesis
Current Drug Targets - Cardiovascular & Hematological Disorders Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting STAT1 in Both Cancer and Insulin Resistance Diseases
Current Protein & Peptide Science Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Prognostic and Predictive Value of Epithelial to Mesenchymal Transitionassociated Markers in Oral Squamous Cell Carcinoma
Current Proteomics Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Identification and Usage of Fluorescent Probes as Nanoparticle Contrast Agents in Detecting Cancer
Current Pharmaceutical Design